FORM PTO-1595 (Rev. 6-93)

05-16-2005



1ERCE Office

RECORDATION FOR PATENTS ONLY

	Attorney Docket No.: 030291-0003
To the Commissioner for Patents	A THORE I DON'T LOOK CATE ATTACK
Please record the attached original documents or copy the	
1. Name of conveying party(ies):	2. Name and address of receiving party(ies):
ZENECA LIMITED (now Syngenta Limited)	ASTRAZENECA UK LIMITED
	15 Stanhope Gate
	London, England W1K 1LN
Additional names of conveying party(ies) attached? NO	
3. Nature of conveyance:	
Security Agreement Change of Name	
Other	
Execution Date: January 4, 2000; May 20, 2004	
Execution Page. Sandary 1, 2000, 114y 20, 2001	
	Additional name(s) & address(es) attached? NO
4. New Application number(s) and/or Patent number(s):	
A. 55 U.S. Patent Number(s):	20
1. U.S. Letters Patent No. 6,541,491 issued April 1, 200	
2. U.S. Letters Patent No. 6,531,605 issued March 11,	2003
-(continued on attached page)-	
D. S.I.C. Detent Annihortion Number(s).	
B. 5 U.S. Patent Application Number(s):	10. 2002
1. U.S. Patent Application No. 10/391,025 filed March	
2. U.S. Patent Application No. 10/348,229 filed Januar	
3. U.S. Patent Application No. 10/293,561 filed Novem	
4. U.S. Patent Application No. 10/101,948 filed March	
5. U.S. Patent Application No. 09/963,686 filed Septem	
If this document is being filed together with a new applica	tion the execution date of the application is
Additional numbers attached: YES (see attached page)	
5. Name and address of party to whom correspondence	6. Total number of applications and patents involved: 60
concerning this document only should be mailed:	o. Total number of applications and patents involved. <u>oo</u>
concerning this document only should be maned.	
Name: Donald J. Bird	7. Total fee (37 C.F.R. §3.41): <u>\$ 2,400.00</u>
Trainer Bonda V. Bhu	, , <u></u>
Internal Address: Morgan, Lewis & Bockius LLP	
Antonia i radi essi i riolgan, Devils & Docklas DDI	$\underline{\mathbf{X}}$ Authorized to be charged to Deposit Account 50-0310
Street Address: 1111 Pennsylvania Ave., N.W.	
City: Washington State: D.C. Zip: 20004	8. Duplicate Cover Sheet attached
9. Statement and Signature	
To the best of my knowledge and belief the foregoing info	ormation, is true and correct and any attached copy is a true
copy of the original document.	of mation and correct and any attached copy is a true
/ /	
Donald J. Bird	May 10, 2.005
Name of Person Signing Signature	Te Mate
Reg. No. 25,323	Date
 	

PATENT REEL: 016547 FRAME: 0256

Total number of pages including cover sheet, attachments and documents: 13

1-WA/2147928.1

-(continued from Item 4A):-

- 3. U.S. Letters Patent No. 6,521,612 issued February 18, 2003
- 4. U.S. Letters Patent No. 6,448,280 issued September 10, 2002
- 5. U.S. Letters Patent No. 6,441,004 issued August 27, 2002
- 6. U.S. Letters Patent No. 6,333,361 issued December 25, 2001
- 7. U.S. Letters Patent No. 6,300,330 issued October 9, 2001
- 8. U.S. Letters Patent No. 6,258,817 issued July 10, 2001
- 9. U.S. Letters Patent No. 6,232,338 issued May 15, 2001
- 10. U.S. Letters Patent No. 6,232,313 issued May 15, 2001
- 11. U.S. Letters Patent No. 6,187,804 issued February 13, 2001
- 12. U.S. Letters Patent No. 6,160,123 issued December 12, 2000
- 13. U.S. Letters Patent No. 6,143,775 issued November 7, 2000
- 14. U.S. Letters Patent No. 6,124,279 issued September 26, 2000
- 15. U.S. Letters Patent No. 6,103,721 issued August 15, 2000
- 16. U.S. Letters Patent No. 6,087,336 issued July 11, 2000
- 17. U.S. Letters Patent No. 6,084,103 issued July 4, 2000
- 18. U.S. Letters Patent No. 6,060,475 issued May 9, 2000
- 19. U.S. Letters Patent No. 6,034,175 issued March 7, 2000
- 20. U.S. Letters Patent No. 6,019,745 issued February 1, 2000
- 21. U.S. Letters Patent No. 5,993,859 issued November 30, 1999
- 22. U.S. Letters Patent No. 5,990,130 issued November 23, 1999
- 23. U.S. Letters Patent No. 5,980,501 issued November 9, 1999
- 24. U.S. Letters Patent No. 5,948,437 issued September 7, 1999
- 25. U.S. Letters Patent No. 5,889,110 issued March 30, 1999
- 26. U.S. Letters Patent No. 5,882,338 issued March 16, 1999
- 27. U.S. Letters Patent No. 5,866,568 issued February 2, 1999
- 28. U.S. Letters Patent No. 5,863,935 issued January 26, 1999
- 29. U.S. Letters Patent No. 5,861,392 issued January 19, 1999
- 30. U.S. Letters Patent No. 5,856,321 issued January 5, 1999
- 31. U.S. Letters Patent No. 5,770,599 issued June 23, 1998
- 32. U.S. Letters Patent No. 5,744,471 issued April 28, 1998
- 33. U.S. Letters Patent No. 5,652,233 issued July 29, 1997
- 34. U.S. Letters Patent No. 5,622,964 issued April 22, 1997
- 35. U.S. Letters Patent No. 5,616,582 issued April 1, 1997
- 36. U.S. Letters Patent No. 5,612,367 issued March 18, 1997
- 37. U.S. Letters Patent No. 5,567,700 issued October 22, 1996
- 38. U.S. Letters Patent No. 5,510,460 issued April 23, 1996
- 39. U.S. Letters Patent No. 5,504,216 issued April 2, 1996
- 40. U.S. Letters Patent No. 5,482,963 issued January 9, 1996
- 41. U.S. Letters Patent No. 5,478,820 issued December 26, 1995
- 42. U.S. Letters Patent No. 5,466,826 issued November 14, 1995
- 43. U.S. Letters Patent No. 5,466,699 issued November 14, 1995
- 44. U.S. Letters Patent No. 5,457,105 issued October 10, 1995
- 45. U.S. Letters Patent No. 5,455,253 issued October 3, 1995
- 46. U.S. Letters Patent No. 5,399,574 issued March 21, 1995
- 47. U.S. Letters Patent No. 5,352,694 issued October 4, 1994
- 48. U.S. Letters Patent No. 5,319,097 issued June 7, 1994
- 49. U.S. Letters Patent No. 5,294,636 issued March 15, 1994
- 50. U.S. Letters Patent No. 5,280,125 issued January 18, 1994
- 51. U.S. Letters Patent No. 5,274,118 issued December 28, 1993
- 52. U.S. Letters Patent No. 5,183,814 issued February 2, 1993
- 53. U.S. Letters Patent No. 4,636,505 issued January 13, 1987
- 54. U.S. Letters Patent No. RE36,617 issued March 14, 2000
- 55. U.S. Letters Patent No. D433,124 issued October 31, 2000

1-WA/2147928.1

ASSIGNMENT

WHEREAS, Syngenta Limited, [hereinafter also referred to as ASSIGNOR], a company created and existing under the Laws of England and Wales, having its Registered Address at Syngenta European regional Centre, Priestly Road, Surrey Research Park, Guilford, Surrey, England GU2 7YH, acquired under its former name, Zeneca Limited, the entire right, title and interest, by assignment, in and to the United States Letters Patent and applications for Letters Patent listed in Appendix A (attached).

AND WHEREAS AstraZeneca UK Limited, [hereinafter also referred to as ASSIGNEE], a company created and existing under the Laws of England and Wales, having its Registered Address at 15 Stanhope Gate, London, England W1K 1LN, has acquired from Zeneca Limited [now, by change of name, Syngenta Limited], by general assignment dated January 4, 2000, the entire right, title and interest in and to the United States Letters Patent and applications for Letters Patent listed in Appendix A (attached), and the invention(s) covered thereby, and is desirous of confirming such acquisition of right, title and interest;

NOW, THEREFORE, in confirmation of a general assignment from Zeneca Limited dated January 4, 2000 [copy attached], and for other valuable consideration, the receipt whereof is hereby acknowledged, the said ASSIGNOR has assigned, sold and transferred, and by these presents does assign, sell and transfer unto the said ASSIGNEE, the entire right, title and interest in and to the said invention(s) in the United States and its territorial possessions, and the entire right, title and interest in and to said listed Letters Patent and applications for Letters Patent, and in and to any and all Letters Patent which may be granted on said applications in the United States and its territorial possessions, and in and to any and all continuations and divisions of said application(s) and reissues and extensions of said Letters Patent, the same to be held and enjoyed by the said ASSIGNEE, its successors, assigns and legal representatives as fully and entirely as the same would have been held and enjoyed by ASSIGNOR if this assignment had not been made.

The Commissioner of Patents and Trademarks is hereby requested and authorized to issue any reissues or extensions of said Letters Patent, and any Letters Patent on said applications, when granted, in the name of AstraZeneca UK Limited as assignee of ASSIGNOR's entire right title and interest in and to the same, for the sole use and enjoyment of said ASSIGNEE, its successors and assigns.

, we can experience and a condition of the condition
IN WITNESS WHEREOF, Syngenta Limited has executed this Assignment
this <u>20</u> day of <u>May</u> , 2004.
Signed by Syngenta Limited (formerly Zeneca Limited)
By:(signature)
(Mr. John Mack)

1-WA/2147395.1

Appendix A:

• •	
U.S. Letters Patent	<u>Issued</u>
6,541,491	April 1, 2003
6,531,605	March 11, 2003
6,521,612	February 18, 2003
6,448,280	September 10, 2002
6,441,004	August 27, 2002
6,333,361	December 25, 2001
6,300,330	October 9, 2001
6,258,817	July 10, 2001
6,232,338	May 15, 2001
6,232,313	May 15, 2001
6,187,804	February 13, 2001
6,160,123	December 12, 2000
6,143,775	November 7, 2000
6,124,279	September 26, 2000
6,103,721	August 15, 2000
6,087,336	July 11, 2000
6,084,103	July 4, 2000
6,060,475	May 9, 2000
6,034,175	March 7, 2000
6,019,745	February 1, 2000
5,993,859	November 30, 1999
5,990,130	November 23, 1999
5,980,501	November 9, 1999
5,948,437	September 7, 1999
5,889,110	March 30, 1999
5,882,338	March 16, 1999
5,866,568	February 2, 1999
5,863,935	January 26, 1999
5,861,392	January 19, 1999
5,856,321	January 5, 1999
5,770,599	June 23, 1998
5,744,471	April 28, 1998
5,652,233	July 29, 1997
5,622,964	April 22, 1997
5,616,582	April 1, 1997
5,612,367	March 18, 1997
5,567,700 5,510,400	October 22, 1996
5,510,460	April 23, 1996

1-WA/2147395.1

Appendix A (continued):

U.S. Letters Patent 5,504,216 5,482,963 5,478,820 5,466,826 5,466,699	Issued April 2, 1996 January 9, 1996 December 26, 1995 November 14, 1995 November 14, 1995
5,457,105 5,455,253 5,399,574 5,352,694 5,319,097 5,294,636 5,280,125 5,274,118 5,183,814 4,636,505 RE36,617	October 10, 1995 October 3, 1995 March 21, 1995 October 4, 1994 June 7, 1994 March 15, 1994 January 18, 1994 December 28, 1993 February 2, 1993 January 13, 1987 March 14, 2000
D433,124	October 31, 2000

U.S. Applications for Letters Patent Filing Date

10/391,025	March 19, 2003
10/348,229	January 22, 2003
10/293,561	November 14, 2002
10/101,948	March 21, 2002
09/963,686	September 27, 2001


1-WA/2147395.1

I JOHN BICKMORE HODGSON of Wilmslow Cheshire England
Notary Public duly authorised admitted and sworn and practising
within the United Kingdom of Great Britain and Northern Ireland do
hereby certify that the Photostat matter hereto annexed is a true copy of
a document the original of which was produced to me at
Macclesfield England

this 13th day of September 2002

John Bickmore Hodgson

Notary Public



REEL: 016547 FRAME: 0261


DE PINNA

I, ELEANOR FRANCES ALISON FOGAN, Notary Public of the City of London and elsewhere in England, duly admitted and sworn, practising in the said City,

DO HEREBY CERTIFY AND ATTEST:

THAT the signature set to the Certification appearing on and in verification of the hereunto annexed copy document relating to the English Company styled "AstraZeneca UK Limited", a Company duly incorporated and existing in accordance with the laws of England, registered at the Companies Registration Office for England and Wales under No. 3674842 and having its Registered Office at 15 Stanhope Gate, London W1Y 6LN, England, is truly that of GRAEME HAROLD RANKINE MUSKER, whose identity I attest, the Secretary of the said Company, and a proper and competent Officer thereof to sign such Certification on its behalf.

IN TESTIMONY WHEREOF I have hereunto set my hand and affixed my Seal of Office in the City of London aforesaid, this twenty-burth day of January in the year two thousand.



55 Piccarilly London WIV OPJ
Teleplante:+44(0) 171 208 2000 Pacsimile: +44 (0) 173 208 0000 DN Na. 48521 Piccarilly 2

- 1	the state of the s
	COTIFIED TRUE COPY OF THE ORIGINAL
T. Contraction	SIGNED.
Contraction.	G. H. R. MUSKER Company Secretary
THE PERSON	DATE 19 JAN 2000
١.,	

4 January 2000

ZENECA LIMITED

ASTRAZENECA UK LIMITED

ASSIGNMENT OF INTELLECTUAL PROPERTY RIGHTS EXCLUDING RIGHTS IN SOFTWARE

FRESHFIELDS

THIS DEED OF ASSIGNMENT is made on 4 January 2000

BETWEEN

ZENECA LIMITED (company no. 2710846) a company incorporated in England whose registered office is at 15 Stanhope Gate, London W1Y 6LN (Zeneca)

ASTRAZENECA UK LIMITED (company no. 3674842) a company incorporated in England whose registered office is at 15 Stanhope Gate, London W1Y 6LN (AZUK)

WHEREAS

- (A) Zeneca is the beneficial owner of the Business IPR.
- (B) Zeneca has agreed to assign the Business IPR to AZUK, on the terms and conditions contained in this Deed.

IT IS AGREED AS FOLLOWS:

DEFINITIONS

- 1.1 Words and expressions used in this Deed shall have the meanings set out in the Schedule, unless the context requires otherwise.
- 1.2 The headings in this Deed shall not affect its interpretation.

ASSIGNMENT

2. Zeneca hereby assigns to AZUK all its right, title and interest in the Business IPR together with all statutory and common law rights attaching thereto including the right to sue for damages and other remedies in respect of any infringement or misuse of the Business IPR.

MAINTENANCE OF REGISTERED RIGHTS

- 3. AZUK will be responsible for the maintenance of the Registered Rights following the date of this Deed, notwithstanding that some Registered Rights may for the time being be held by or registered in the name of Zeneca. Zeneca undertakes to do the following, at AZUK's cost, pending formal registration of the assignment of each Registered Right to AZUK in each relevant jurisdiction:
- (a) if legally required, to pay all registration, renewal and other afficial and professional costs and fees relating to the Registered Right as they fall due;
- (b) if legally required, to use best endeavours to promptly satisfy all afficial actions issued by any relevant trade mark, patent or other registry in respect of the Registered Right;
- (c) to notify AZUK as soon as it becomes aware of any actual or threatened infringement of any Registered Right or any form of attack, allegation or complaint relating to the Registered Right;

LO993470.131/15+

- (d) to provide AZUK with all information and assistance reasonably required by AZUK for AZUK to conduct any claim, action or proceedings relating to the Registered Right, and, subject to the terms of the Licence of Intellectual Property Rights Excluding Rights in Trade Marks and Software and the Trade Mark Licence between AZUK and Zeneca of even date (the *Licences*), not to make any admission of liability, agreement or compromise with any third party or body in relation to the Registered Right without AZUK's prior written consent (such consent not to be unreasonably withheld or delayed);
- (e) to ensure that copies of all correspondence which it or its agents receive in respect of the Registered Right (including any renewal advice or other notification received from any relevant registry) are promptly delivered to AZUK, marked for the attention of D.E. Giles, Intellectual Property Department, Mereside, Alderley Park, Macclesfield, Cheshire or such other person as AZUK may notify to Zeneca from time to time;
- (f) subject to the terms of the Licences, not to assign, transfer or charge (nor grant any licence in respect of) or otherwise encumber the Registered Right without AZUK's prior written consent; and
- (g) at AZUK's request, to assist AZUK so far as is reasonably necessary to achieve cancellation of the Registered Right.

CATEGORISATION OF INTELLECTUAL PROPERTY RIGHTS

- 4.1 Either party may, within 12 months from the date of this Deed or until the date on which Zeneca and AZUK cease to be part of the same Group (whichever occurs sooner), object to the categorisation or non-categorisation of any Intellectual Property Rights as Business IPR by providing written notice to the other party of its objection giving full reasons why it believes such Intellectual Property Rights have been incorrectly categorised.
- 4.2 If the parties agree in writing that any Intellectual Property Rights, based on the criteria set out in this Deed:
- (a) have not been correctly categorised as Business IPR, then such Intellectual Property Rights shall be recategorised accordingly and shall be governed by the terms and conditions of this Deed; or
- (b) have been wrongly categorised as Business IPR, then AZUK shall take all steps reasonably required (including executing any documents necessary) to assign any right, title and interest as it has in the relevant Intellectual Property Rights to Zeneca.
- 4.3 If any dispute shall arise between AZUK and Zeneca as regards the categorisation of any Intellectual Property Rights pursuant to this Deed, the dispute shall be resolved in accordance with Clause 5.
- 4.4 The parties acknowledge and agree that all right, title and interest in and to any form or combination of the "ZENECA" trade mark and name, and any domain name

LQ993470.131/15+

incorporating the "ZENECA" name, shall be assigned to AZUK and shall not be subject to recategorisation pursuant to this Clause.

DISPUTES

- 5.1 If there is a dispute between the parties arising out of this Deed and at the time the parties have the same ultimate holding company, then either party may give notice that it wishes to resolve the dispute in accordance with this Clause in which case:
- (a) the parties shall use all reasonable endeavours to resolve the matter on an amicable basis;
- (b) if the dispute has not been resolved 21 days after a notice is given under this Clause, responsibility for resolution of the dispute shall be referred to the Chief Financial Officer (or his nominee) of AZUK and the Chief Executive Officer of Zeneca (or his nominee); and
- (c) if the dispute has not been resolved under (b) after a further 60 days it shall be referred to the Chairman of the ultimate holding company for resolution. The parties agree that the decision of the Chairman shall be final and binding.
- 5.2 If there is a dispute between the parties arising out of this Deed and at the time the parties do not have the same ultimate holding company, then either party may give notice that it wishes to resolve the dispute in accordance with this Clause in which case:
- (a) the parties shall use all reasonable endeavours to resolve the matter on an amicable basis;
- (b) if the dispute has not been resolved 21 days after such a notice is given, responsibility for resolution of the dispute shall be referred to the Chief Financial Officer of AZUK (or his nominee) and the Chief Executive Officer of the ultimate holding company of Zeneca (or his nominee); and
- (c) if the dispute has not been resolved under (b) after a further 60 days then either party shall be free to serve proceedings in accordance with Clause 8.2.

COUNTERPARTS

6. This Deed may be executed in any number of counterparts and by the parties to it on separate counterparts, each of which is an original but all of which together constitute one and the same instrument.

FURTHER ASSURANCE

7.1 Zeneca agrees to perform (or procure the performance of) all further acts and things, and execute and deliver (or procure the execution and delivery of) such further documents, as may be required by law or as AZUK may reasonably require, at AZUK's cost, to implement and/or give effect to this Deed and for the purpose of vesting in AZUK the full benefit of the rights assigned to AZUK under this Deed, including executing as soon as reasonably practicable after the date of this Deed such

1.0993470.131/15+

deeds, agreements or other documents as may be required by AZUK to effect the registration or recordal of the assignment of the Registered Rights to AZUK in each relevant jurisdiction.

7.2 Without limiting Clause 7.1, the parties shall use all reasonable endeavours to produce an agreed list of the Registered Rights as soon as reasonably practicable, and in any case within 90 days, after the date of this Deed.

GOVERNING LAW

- 8.1 This Deed and the relationship between the parties shall be governed by, and interpreted in accordance with, English law.
- 8.2 The parties irrevocably agree that the courts of England are to have exclusive jurisdiction to settle any disputes which may arise out of, or in connection with, this Deed.

IN WITNESS WHEREOF this Deed has been executed by the duly authorised representatives of the parties the day and year first above written.

SIGNED by UNATHAN D SULIAN)
for and on behalf of

ZENECA LIMITED

in the presence of:

Selected Sweet Links

SIGNED by SHAVA GRADY
for and on behalf of

ASTRAZENECA UK LIMITED

in the presence of:

J. E. Lang

Solicitan

GS Fleet Street

SCHEDULE

Definitions

Business IPR means all Intellectual Property Rights owned by Zeneca, other than Intellectual Property Rights which prior to the date hereof were used in and related exclusively or predominantly to the Retained Business or the Quom Business; Business IPR includes, without limitation, all rights in any form or combination of the "ZENECA" trade mark and name, and any domain name incorporating the "ZENECA" name;

Group means, in relation to either party, that party and any company which is for the time being a subsidiary or holding company of that party (as defined by Section 736 of the Companies Act 1985) or a company which is a subsidiary of any such holding company;

Intellectual Property Rights means patents, trade marks, service marks, trade names, internet domain names, design rights, copyright and moral rights, rights in know-how, rights in secret or confidential information, rights in supplementary protection certificates, and other intellectual property rights, in each case whether registered or unregistered and including applications for the grant of any of the foregoing and all rights or forms of protection having equivalent or similar effect anywhere in the world and any divisionals, continuations, continuations in part, extensions, reissues and reexaminations of the same; excluding any patents, patent applications, design rights, copyright and moral rights, rights in know-how or other similar rights in respect of Software, and, for the avoidance of doubt, any registrations obtained from pharmaceutical or agrochemical regulatory authorities;

Quorn Business shall have the meaning given in the Transfer Agreement;

Registered Rights means, in relation to any jurisdiction, any Business IPR which are the subject of registration (or application for registration) with any competent authority in that jurisdiction; and Registered Right means any one of them;

Retained Business shall have the meaning given in the Transfer Agreement;

Software means any software applications and any associated source code, object code and documentation:

Transfer Agreement means the Agreement for the sale and purchase of part of the business of Zeneca between Zeneca and AZUK of even date.

LQ993470.131/15+

PATENT REEL: 016547 FRAME: 0268

RECORDED: 05/10/2005